The treatment of benign prostatic hyperplasia by means of transurethral holmium laser enucleation.
- Author:
Shu-Jie XIA
1
;
Jiang ZHU
;
Jun LU
;
Jie FAN
;
Wei WEN
;
Jie ZHANG
;
Wei-Guo LI
;
Yi-Yong ZHU
;
Dong-Ya WANG
;
Gui-Ming LING
;
Xian-You ZHANG
;
Xiao-Da TANG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Follow-Up Studies; Holmium; Humans; Laser Therapy; Male; Middle Aged; Prostate; pathology; Prostatic Hyperplasia; pathology; surgery; Transurethral Resection of Prostate; methods
- From: National Journal of Andrology 2003;9(4):257-259
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVESTo evaluate the clinical effect of the holmium laser enucleation and morcellation of prostate (HoLEP) in the treatment of benign prostatic hyperplasia(BPH).
METHODSIn the treatment of 35 BPH patients, 100 watt high-powered holmium laser set was used transurethrally and a reciprocating blade tissue morcellator was introduced via a nephroscope to enucleate and morcellate the prostatic tissue.
RESULTSOperations in all 35 cases were successful. The average operation time was 60 +/- 23.2 (range 30-180) min. The removed prostatic tissue weighed 31 +/- 9 (range 10-56) g on average. The average catheter time was 1.5 d (from 20 h to 4 d). No blood transfusion was performed in all cases. Histopathological analysis confirmed the diagnosis of BPH in all cases. In the 3-month follow up of 32 cases, IPSS dropped from 24 +/- 6.2 to 5.6 +/- 3.6; the peak urinary flow rate(Qmax) went up from 8.5 +/- 3.9 ml/s to 22.0 +/- 7.2 ml/s; the residual volume of urine dropped from 138 +/- 125 ml to 21 +/- 15 ml. No serious complications were found.
CONCLUSIONSHoLEP is effective in treating BPH. It can completely enucleate the hyperplastic tissue with little bleeding in operation. The treatment has the advantages of short catheter time and significant clinical improvements.
